MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$3,130,667
EPS
-$0.62
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
1,887,168
1,204,090
1,283,956*
1,143,178
General and administrative
1,329,726
1,677,697
1,186,379.5*
1,846,495
Change in fair value of related party note
0
0
-682,184.5*
193,921
Operating loss
-3,216,894
-2,881,787
-1,788,151*
-3,183,594
Interest income, net
72,884
80,834
96,997.5*
55,151
Other income (expense), net
15,809
58,585
-114,916.5*
240,734
Net loss
-3,128,201
-2,742,368
-1,806,070*
-2,887,709
Foreign currency translation gain (loss)
-2,466
21,490
-42,830.5*
27,204
Comprehensive loss
-3,130,667
-2,720,878
-1,848,900.5
-2,860,505
Basic EPS
-0.62
-0.57
-0.422
-0.65
Diluted EPS
-0.62
-0.57
-0.422
-0.65
Basic Average Shares
5,023,450
4,797,833
4,386,156
4,443,262
Diluted Average Shares
5,023,450
4,797,833
4,386,156
4,443,262
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$3,130,667
(27.10%↑ Y/Y)
Net loss
-$3,128,201
(26.18%↑ Y/Y)
Foreign currency
translation gain (loss)
-$2,466
(95.66%↑ Y/Y)
Interest income, net
$72,884
(20843.68%↑ Y/Y)
Other income
(expense), net
$15,809
(108.51%↑ Y/Y)
Operating loss
-$3,216,894
(20.62%↑ Y/Y)
Research and development
$1,887,168
(2.61%↑ Y/Y)
General and
administrative
$1,329,726
(-28.09%↓ Y/Y)
Buy us a coffee
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)